UBS Asset Management Americas Inc. lessened its stake in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 3.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 151,363 shares of the biopharmaceutical company’s stock after selling 5,844 shares during the period. UBS Asset Management Americas Inc. owned 0.61% of Intercept Pharmaceuticals worth $18,326,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 1,270,984 shares of the biopharmaceutical company’s stock valued at $143,749,000 after acquiring an additional 56,952 shares during the last quarter. State Street Corp increased its position in Intercept Pharmaceuticals by 7.3% during the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock worth $91,110,000 after purchasing an additional 54,523 shares during the last quarter. First Trust Advisors LP increased its position in Intercept Pharmaceuticals by 17.0% during the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock worth $34,797,000 after purchasing an additional 41,856 shares during the last quarter. Macquarie Group Ltd. increased its position in Intercept Pharmaceuticals by 54.2% during the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock worth $27,321,000 after purchasing an additional 84,954 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in Intercept Pharmaceuticals by 13.1% during the first quarter. Point72 Asset Management L.P. now owns 220,600 shares of the biopharmaceutical company’s stock worth $24,950,000 after purchasing an additional 25,500 shares during the last quarter. 82.19% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CMO David Shapiro sold 1,250 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $117.43, for a total transaction of $146,787.50. Following the completion of the sale, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 253 shares of the stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $111.31, for a total transaction of $28,161.43. Following the sale, the insider now directly owns 23,324 shares of the company’s stock, valued at approximately $2,596,194.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,354 shares of company stock worth $521,797. Company insiders own 4.50% of the company’s stock.

A number of equities analysts have commented on ICPT shares. Royal Bank Of Canada lifted their target price on shares of Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 26th. Wedbush reissued an “outperform” rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Cantor Fitzgerald restated an “underweight” rating and set a $69.00 price target (up previously from $60.00) on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. Finally, Jefferies Group LLC restated a “buy” rating and set a $135.00 price target (down previously from $275.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $162.88.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 59.55 on Tuesday. Intercept Pharmaceuticals, Inc. has a 12-month low of $54.98 and a 12-month high of $163.63. The firm’s market capitalization is $1.49 billion. The firm’s 50-day moving average is $96.24 and its 200-day moving average is $111.82.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($3.14) earnings per share. Equities research analysts forecast that Intercept Pharmaceuticals, Inc. will post ($13.99) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/ubs-asset-management-americas-inc-has-18-33-million-stake-in-intercept-pharmaceuticals-inc-icpt/1604940.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.